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LETTERS TO THE EDITOR
Patients With High-Risk
Acute Myocardial Infarction Randomized
to One of Two Treatment
Strategies: Delay and Eligibility Questions
Grines et al. (1) reported randomization of patients with high-risk
acute myocardial infarction (AMI) to one of two treatment
strategies, namely transfer for primary percutaneous transluminal
coronary angioplasty (PTCA) or on-site thrombolysis. Random-
ization required a mean of 44 min (median 32 min) and resulted in
a mean delay of 63 min (median 51 min) from emergency room
arrival to delivery of thrombolytic treatment. The time from
symptom onset to emergency room arrival was not presented. This
time interval is important for judging the impact of the reported
treatment delay on mortality (2).
In addition, it would be interesting to know the proportion of
patients eligible for the study, that is, the numbers of AMI patients
screened, number of patients matching high-risk criteria, and
number of those excluded.
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Safety and Benefits of Transferring
Patients With Acute Myocardial
Infarction to Interventional
Center for Immediate Angioplasty
The study by Grines et al. (1), which appeared recently in JACC,
evaluated the safety and benefits of transfer of a high-risk patient
suffering an acute myocardial infarction (AMI) to a regional
interventional center for immediate angioplasty. The investigators
concluded: “This trial demonstrated that patients with high-risk
AMI at hospitals without percutaneous transluminal coronary
angioplasty (PTCA) capabilities might have an improved outcome
if transferred for emergency PTCA rather than being treated with
thrombolytic therapy.” In the editorial (2) that accompanied the
study, Cannon and Baim stated “it appears that there may be
benefit in prompt and efficient transfer of patients from a com-
munity hospital that does not offer primary percutaneous coronary
intervention (PCI) to a nearby one that does.” This begs an
important question concerning the safety of transferring a patient
with AMI. The investigators note that their study is underpowered
to answer the question. The difficulty in recruitment of subjects
and premature closure of the study suggest that the study group is
a highly selective set of patients. Before the availability of imme-
diate angioplasty it was believed that transfer was inappropriate for
the AMI patient. This patient is at the greatest danger for
extension of the infarction, serious arrhythmia, and congestive
heart failure in the first hours after the infarction. Monitoring for
and managing these complications are very difficult when the
patient is transferring from one hospital to another.
Cannon and Baim (2) noted that success for PCI is related to
the skill and experience of the interventionalist. Many hospitals
with catherization laboratories have the availability of high-volume
interventionalists. However, the majority of these physicians are
unwilling to perform interventions at hospitals that do not rou-
tinely perform angioplasty. Because it is not a routine procedure,
PTCA performed under emergency circumstances would represent
a higher risk for the patient. As a solution to this problem, Cannon
and Baim suggested a network of cardiac centers offering PCI
around the clock.
Could immediate angioplasty be safely and effectively applied at
the initial hospital? I believe that it is safer to bring the interven-
tion to the patient rather than the patient to the interventionalist.
For most patients with an AMI, this could be accomplished by
expanding PTCA to any hospital with a catheterization laboratory.
The use of routine PTCA at hospitals without back-up cardiovas-
cular surgery would significantly extend PCI to the at-risk popu-
lation and increase the availability of skilled interventionalists to
provide the service.
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REPLY
In response to correspondents Pechlaner and Bellmann, the time
from symptom onset to emergency room arrival was 140 46 min
in the transfer arm and 158 162 min in the lytic arm (p 0.40).
Unfortunately, screening logs were not maintained, and we were
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unable to determine the proportion of AMI acute myocardial
infarction (AMI) patients eligible for enrollment in the study.
Dr. Silverman questioned the safety of transfer of the AMI
patient. Although his concerns are valid, all emergency medical
systems that would be transferring AMI patients are trained in
advanced cardiac life support. These systems should be able to
resuscitate AMI patients, as well as the staff in the emergency
department or intensive care units of small hospitals.
In fact, five randomized trials of transfer for primary angioplasty
have shown that transfer is safe and is associated with better
outcomes compared to on site thrombolytics (1–5) (Table 1).
Experienced angioplasty operators may safely perform primary
angioplasty in diagnostic catheterization laboratories. However,
the expense of training staff, both in the laboratory and in recovery
units, in addition to stocking expensive angioplasty equipment,
may not be feasible in small hospitals.
Finally, it would be far easier to instruct emergency medical staff
drivers to head in the correct direction—toward a primary angio-
plasty facility.
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Possible Risks to Patients Receiving
Statins Combined With Other Medications
The American College of Cardiology/American Heart Associa-
tion/National Heart Lung, and Blood Institute (ACC/AHA/
NHLBI) Clinical Advisory on Statins (1) was a timely review of an
important issue, but I believe that additional information on the
issue of drug interactions would be helpful to clinicians who
manage patients receiving statins with other medications.
First, as for combining statins with CYP3A4 inhibitors, only
lovastatin and simvastatin undergo extensive (90% or more)
presystemic metabolism by CYP3A4 in the gut wall and liver (2).
Hence, the risk of statin-induced myopathy due to CYP3A4
inhibitors appears to be considerably greater for lovastatin and
simvastatin compared to the other statins. For example, potent
CYP3A4 inhibitors such as itraconazole can produce 10- to
20-fold increases in the serum concentrations of lovastatin or
simvastatin (3,4). Atorvastatin is also metabolized by CYP3A4,
but it does not undergo as extensive presystemic metabolism as
lovastatin and simvastatin. Accordingly, potent CYP3A4 inhibi-
tors tend to produce two- to four-fold increases in atorvastatin
serum concentrations (5,6). Pravastatin is not metabolized by
CYP3A4 or other cytochrome P450 isozymes, and inhibition of
CYP3A4 has little effect on its pharmacokinetics (4,6). Fluvastatin
is metabolized primarily by CYP2C9 and also is unlikely to
interact with CYP3A4 inhibitors (2).
Second, as for macrolides and statins, erythromycin and clar-
ithromycin are correctly listed as potentially increasing the risk of
statin-associated myopathy. As described above, this caution re-
sults from the ability of these two macrolide antibiotics to inhibit
the CYP3A4 metabolism of lovastatin, simvastatin, and to a lesser
extent atorvastatin (7,8). But a separate bullet point lists “Macro-
lide antibiotics” (page 571 under “Prevention” heading). This
might lead some readers to conclude that azithromycin and
dirithromycin interact with statins, but substantial evidence sug-
gests that these macrolides do not inhibit CYP3A4 (9).
Finally, as for the interaction of calcium-channel blockers and
statins, verapamil—a known CYP3A4 inhibitor—is listed as
increasing the risk of statin-associated myopathy, but diltiazem is
not mentioned. Available evidence suggests that verapamil and
diltiazem are roughly equivalent (moderate) inhibitors of
CYP3A4. Indeed, diltiazem has been shown in pharmacokinetic
studies to increase serum concentrations of both lovastatin and
simvastatin (10,11), and isolated cases of myopathy have been
reported in patients receiving simvastatin plus diltiazem (12,13).
Table 1. Pooled Outcomes From Five Studies of Transfer for Primary PTCA Versus On Site:
Lytics
PCI Lytic p Value
Odds
Ratio 95% CI
Death 103/1,468 (7.0%) 129/1,443 (8.9 %) 0.055 1.3 0.99–1.70
Nonfatal reMI 19/1,037 (1.8%) 68/1,022 (6.7 %)  0.0001 3.82 2.28–6.40
Total stroke 11/1,037 (1.1%) 22/1,022 (2.2 %) 0.049 2.05 0.99–4.25
Death/stroke/MI 121/1,468 (8.2%) 217/1,443 (15.0%)  0.0001 1.97 1.56–2.49
CI  confidence interval; MI  myocardial infarction; PCI  percutaneous coronary intervention.
519JACC Vol. 41, No. 3, 2003 Letters to the Editor
February 5, 2003:518–20
